Atrial natriuretic peptide production and natriuretic peptide receptors in the human uterus and their effect on myometrial relaxation.
OBJECTIVE
The objective of the study was to identify the effect of atrial natriuretic peptide (ANP) on uterine contractility, production of ANP, and natriuretic peptide receptor (NPR) expression in human myometrial tissue.


METHODS
In an institutional review board-approved study, gravid human myometrium was obtained from patients undergoing cesarean section. Uterine contractility was examined using isometric force tension studies. After regular uterine contractions were obtained with oxytocin, ANP was added in increasing concentrations. ANP concentration was measured from myometrial tissue using radioimmunoassay (RIA). Primary myometrial cell culture was performed and treated with nifedipine vs oxytocin. RIA was performed on these cells and the cell culture media. Western blot analysis was performed on uterine tissue samples for natriuretic peptide receptors.


RESULTS
With increasing concentration of ANP (starting at 3 pM), myometrial contraction frequency decreased. ANP was identified in primary cultured myometrial cells and cell culture media. Myometrial ANP concentration increased with advancing gestational age. The concentration of ANP decreased within myometrial cells treated with oxytocin. The amount of ANP in the cell culture media increased from cells treated with nifedipine. Western blot identified NPR-A, -B, and -C in myometrial tissue. NPR-A expression was significantly increased in preterm samples.


CONCLUSIONS
ANP has a dose dependent effect on uterine relaxation. ANP is present in human myometrial cells and appears to be secreted by myometrial cells. The concentration of ANP may vary with gestational age and modulators of uterine contractility. NPR-A, -B, and -C receptor proteins are present in myometrial tissue. NPR-A levels may correlate with gestational age.
Cootauco
Alice C
AC
Division of Maternal-Fetal Medicine, Department of Gynecology and Obstetrics, Johns Hopkins School of Medicine, Baltimore, MD, USA. alicejchung6@yahoo.com
Murphy
Jamie D
JD
Maleski
Jerome
J
Blakemore
Karin J
KJ
Slodzinski
Martin K
MK
D009320:Atrial Natriuretic Factor / Q000096:biosynthesis / Q000494:pharmacology*; D026481:Blotting, Far-Western; D002478:Cells, Cultured; D004305:Dose-Response Relationship, Drug; D005260:Female; D005865:Gestational Age; D006801:Humans; D009215:Myometrium / Q000378:metabolism*; D009543:Nifedipine / Q000494:pharmacology; D010120:Oxytocics / Q000494:pharmacology; D010121:Oxytocin / Q000494:pharmacology; D011863:Radioimmunoassay; D017461:Receptors, Atrial Natriuretic Factor / Q000378:metabolism*; D015149:Tocolytic Agents / Q000494:pharmacology; D014590:Uterine Contraction / Q000187:drug effects* / Q000378:metabolism; D000099242:Atrial Natriuretic Factor Receptor B
D009320:Atrial Natriuretic Factor; D009543:Nifedipine; D010120:Oxytocics; D010121:Oxytocin; D017461:Receptors, Atrial Natriuretic Factor; D015149:Tocolytic Agents; D000099242:Atrial Natriuretic Factor Receptor B; C091715:atrial natriuretic factor receptor A; C073616:atrial natriuretic factor receptor C